Probiotic composition and use thereof

US11291697B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11291697-B2
Application numberUS-201916520359-A
CountryUS
Kind codeB2
Filing dateJul 24, 2019
Priority dateFeb 20, 2019
Publication dateApr 5, 2022
Grant dateApr 5, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure relates to the field of microbial technology, and discloses a probiotic composition and use thereof. The probiotic composition in the present disclosure is consisted of Bifidobacterium adolescentis CCFM8630, Lactobacillus reuteri CCFM8631 and Lactobacillus rhamnosus CCFM1044, whose effect of alleviating metabolic syndrome is significantly better than that of CCFM8630 or CCFM8631 alone or combination of the two, especially in aspects of lowering epididymal fat content, lowering fasting blood glucose level, lowering the area under sugar tolerance curve and lowering contents of serum low density lipoprotein and total cholesterol, improving liver antioxidant capacity and lowering serum IL-1β content, etc. The extent of decrease or increase is increased by 9.62% to 769.62% compared with formulations of a single probiotic or a combination of two probiotics. The combination of three probiotics achieves a significant synergistic effect.

First claim

Opening claim text (preview).

The invention claimed is: 1. A probiotic composition, consisting of Bifidobacterium adolescentis CCFM8630 , Lactobacillus reuteri CCFM8631 and Lactobacillus rhamnosus CCFM1044; wherein ratio of viable count of the Bifidobacterium adolescentis CCFM8630, the Lactobacillus reuteri CCFM8631 and the Lactobacillus rhamnosus CCFM1044 is 1:(1-10):(1-10). 2. A method for preparing the probiotic composition according to claim 1 , comprising, respectively inoculating bacteria solutions of Bifidobacterium adolescentis CCFM8630 , Lactobacillus reuteri CCFM8631 and Lactobacillus rhamnosus CCFM1044 to modified MRS culture medium, culturing at 35-37° C. under anaerobic conditions for 18-24h, and collecting thalli; respectively resuspending the thalli with a freeze-drying protective agent so that the content of each thallus is above 10 10 CFU/mL, then culturing the suspension at 37° C. under anaerobic conditions for 40-60 min, drying to obtain freeze-dried bacterial powder of each thallus, resuspending and diluting, and spreading on a plate to determine the viable count in the bacterial powder; and compounding and mixing the freeze-dried bacterial powder of Bifidobacterium adolescentis CCFM8630, the freeze-dried bacterial powder of Lactobacillus reuteri CCFM8631 and the freeze-dried bacterial powder of Lactobacillus rhamnosus CCFM1044 in a certain proportion such that ratio of viable count of the Bifidobacterium adolescentis CCFM8630, the Lactobacillus reuteri CCFM8631 and the Lactobacillus rhamnosus CCFM1044 is 1:(1-10):(1-10). 3. The method according to claim 2 , wherein the modified MRS culture medium (mMRS) is an MRS culture medium that contains 0.05% of L-cysteine hydrochloride; the freeze-drying protective agent is an aqueous solution that contains 100 g/L-150 g/L skimmed milk powder, 30 g/L-100 g/L sucrose and 30 g/L-100 g/L trehalose; and the drying is a vacuum freeze drying that is carried out after pre-freezing at −15 to 20° C. for 8 to 14h. 4. A method for alleviating metabolic syndrome, comprising using the probiotic composition according to claim 1 . 5. The method according to claim 4 , wherein the probiotic composition is in the form of a health care food or a medicine. 6. The method according to claim 5 , wherein the health care food is a microbial agent or a fermented food. 7. A microbial agent containing the probiotic composition according to claim 1 . 8. The microbial agent according to claim 7 , wherein viable count of the probiotic composition is more than 1×10 11 CFU/g.

Assignees

Inventors

Classifications

  • Bacteria or derivatives thereof, e.g. probiotics · CPC title

  • Antihyperlipidemics · CPC title

  • Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms (removing undesirable substances A23L11/30; soy sauce A23L27/50) · CPC title

  • Free radical scavengers or antioxidants · CPC title

  • Lactobacilli, e.g. L. acidophilus or L. brevis · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11291697B2 cover?
The present disclosure relates to the field of microbial technology, and discloses a probiotic composition and use thereof. The probiotic composition in the present disclosure is consisted of Bifidobacterium adolescentis CCFM8630, Lactobacillus reuteri CCFM8631 and Lactobacillus rhamnosus CCFM1044, whose effect of alleviating metabolic syndrome is significantly better than that of CCFM8630 or C…
Who is the assignee on this patent?
Infinitus China Co Ltd
What technology area does this patent fall under?
Primary CPC classification A61K35/745. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).